LibraryBy pinki shah / May 14, 2022 Speciality — Amyotrophic Lateral Sclerosis (ALS) Biomarkers Biosimilars Bladder Blood Bone Brain Breast Cancer Central Nervous System (CNS) Clinical Trials Colon Colorectal Diversity, Equity & Inclusion Featured Content Gastrointestinal Genitourinary Genomic Geriatric Gynecology Head and Neck Hematologic Hematologic Maglinencies Hematology Immunotherapy Interventional Radiology Kidney Leukemia Liquid Biopsy Liver Lung Lymphoma Malignencies Melanoma Myelodysplastic Syndrome Myeloma Neuroendocrine Novel Oral & Maxillofacial Surgery Ovarian Pancreas Pancreatic Pharmacological Prostate Radiation Radiology Renal Sarcoma Skin Solid Tumor Supportive & Palliative Care Survivorship Telemedicine Thoracic Thrombosis Thymic Thyroid Urothelial Author / Speaker Title of Presentation Type of Media — Video Document Audio Event 2024 Event — 2025 MaTOS Breast 2025 MaTOS GU 2025 PRIMO 2025 South Florida GI Cancer Symposium 2025 Winter Cancer Symposium (WCS) 2024 Advances in Oncology Conference 2024 Best of WCLC San Francisco 2024 California Cancer Consortium Conference (CCC) 2024 MaTOS Lungs 2024 MLS Cleveland 2024 MLS Irvine 2024 MLS Nashville 2024 MLS New Orleans 2024 MLS Seattle 2024 New Orleans Summer Cancer Meeting (NOSCM) 2024 PACC Miami 2024 PRIMO 2024 SPS Puerto Rico 2024 SPS Seattle 2024 SPECTRUM 2024 Sylvester APP Oncology Symposium 2024 Updates in Cancer Therapies 2024 WCS Clear Displaying 1,826 - 1,850 of 2,995 « 1 … 72 73 74 75 76 … 120 » Targeted Therapy for NSCLC By: Jonathan Riess, MD, MS View PDF Lung Cancer Case By: Jonathan Riess, MD, MS View PDF Updates in Targeted Therapies for NSCLC By: Jonathan Riess, MD, MS View PDF Lung Cancer Case By: Jonathan Riess, MD, MS View Video Targeted Therapy for NSCLC By: Jonathan Riess, MD, MS View Video ALK, ROS1 & BRAF Mutations in NSCLC By: Jonathan Riess, MD, MS View Video ALK, ROS1 & BRAF Mutations in NSCLC By: Jonathan Riess, MD, MS View PDF Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy By: Jonathan Riess, MD, MS View PDF Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy By: Jonathan Riess, MD, MS View Video Updates in Targeted Therapy for NSCLC By: Jonathan W. Reiss (UCD) View PDF Updates in Targeted Therapy for NSCLC By: Jonathan W. Reiss, MD, MS View PDF New Therapeutic Directions in Lung Cancer By: Jonathan W. Riess, MD View PDF New Therapeutic Directions in Lung Cancer By: Jonathan W. Riess, MD View Video Target Therapy Updates By: Jonathan W. Riess, MD View PDF Evolving Treatment Options in EGFR-mutant NSCLC By: Jonathan W. Riess, MD, MS View PDF Other Immunotherapy Targets & Agents- Advanced NSCLC By: Jonathan W. Riess, MD, MS View PDF PD - 1 / PD - L1 Directed Immunotherapy for Advanced NSCLC By: Jonathan W. Riess, MD, MS View PDF PD-1/PD-L1 Directed Immunotherapy for Advanced NSCLC By: Jonathan W. Riess, MD, MS View Video Updates in Targeted Therapy for NSCLC By: Jonathan W. Riess, MD, MS View Video Stage IV KRAS Mutant Lung Cancer Case By: Jonathan W. Riess, MD, MS View PDF PD-1/PD-L1 Directed Immunotherapy for Advanced NSCLC By: Jonathan W. Riess, MD, MS View PDF PD-1/PD-L1 Directed Immunotherapy for Advanced NSCLC By: Jonathan W. Riess, MD, MS View Video Stage IV KRAS Mutant Lung Cancer Case By: Jonathan W. Riess, MD, MS View Video Updates in Targeted Therapy for NSCLC By: Jonathan W. Riess, MD, MS View PDF Updates in Targeted Therapy for NSCLC By: Jonathan W. Riess, MD, MS View Video
